摘要
背景与目的:高迁移率族蛋白1(high mobility group box 1,HMGB1)参与DNA复制、转录及翻译过程,与恶性肿瘤的发生、发展、浸润及转移密切相关,并参与炎症、免疫、增殖、转移和自噬等多种信号转导通路的调节。探究HMGB1与乳腺癌患者临床病理学特征、免疫功能及新辅助化疗效果的相关性。方法:选取2019年5月—2020年10月南昌市第三医院收治并接受新辅助化疗的乳腺癌患者120例,采用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)测定患者空芯针穿刺活检物中的HMGB1水平,以及调节性T细胞(regulatory T cell,Treg)相关指标IL-10、TGF-β的含量。采用流式细胞术检测CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞和自然杀伤(natural killer,NK)细胞百分比。采用速率散射比浊法检测免疫球蛋白IgG、IgA、IgM和补体C3、C4的含量。按照95%CI下限水平将研究对象分为高水平组(HMGB1>22.98 ng/mL)和低水平组(HMGB1≤22.98 ng/mL)。新辅助化疗方案的疗程结束后,根据Miller-Payne病理学反应性分级标准评价术后疗效,分析HMGB1水平与疗效的关系。结果:HMGB1与乳腺癌临床分期、淋巴结是否发生转移相关(P<0.05);HMGB1与Treg相关指标IL-10、TGF-β显著相关(r=0.734,P<0.001;r=0.686,P<0.001);HMGB1高水平组CD4^(+)T细胞/CD3^(+)T细胞低于低水平组,CD8^(+)T细胞/CD3^(+)T细胞高于低水平组(P<0.05);高水平HMGB1患者术后疗效差。结论:HMGB1水平与乳腺癌临床分期、淋巴结转移及细胞免疫功能相关,并有助于预测新辅助化疗的效果。
Background and purpose:High mobility group box 1(HMGB1),which is involved in the process of DNA replication,transcription and translation,is closely related to the occurrence,development,invasion and metastasis of malignant tumors.In addition,HMGB1 is involved in the regulation of various signaling pathways of inflammation,immunity,proliferation,metastasis and autophagy.This research aimed to explore the correlation between HMGB1 and clinicopathological characteristics,immune function and neoadjuvant chemotherapy in patients with breast cancer.Methods:We enrolled a total of 120 breast cancer patients admitted to the Third Hospital of Nanchang from May 2019 to October 2020.The level of HMGB1 in sample of the core needle biopsy was determined by enzyme-linked immunosorbent assay(ELISA).IL-10 and TGF-βas the indicators of regulatory T cell(Treg)were measured.The percentages of CD3^(+),CD4^(+),CD8^(+)T lymphocytes and natural killer(NK)cells were detected by flow cytometry.The contents of immunoglobulin IgG,IgA,IgM and complement C3,C4 were determined by rate-scattering turbidimetry.The study subjects were divided into the high level group(HMGB1>22.98 ng/mL)and the low level group(HMGB1≤22.98 ng/mL)according to the lower limit level of the 95%CI.After neoadjuvant chemotherapy,the pathological effect was evaluated according to the Miller-Payne pathological response grading standard.We analyzed the relationship between HMGB1 level and pathological efficacy.Results:HMGB1 levels were associated with breast cancer stage and lymph node metastasis(P<0.05).The level of HMGB1 was significantly correlated with Treg related IL-10 and TGF-β(r=0.734,P<0.001;r=0.686,P<0.001).CD4^(+)T cells/CD3^(+)T cells in the HMGB1 high level group were lower than in the low level group,and CD8^(+)T cells/CD3^(+)T cells were higher in the high level group than in the low level group(P<0.05).Patients with high-level HMGB1 had worse postoperative effects.Conclusion:The level of HMGB1 is related to breast cancer stage,lymph node metastasis and cellular immune function,and helps predict the efficacy of neoadjuvant chemotherapy.
作者
张小艳
李清祥
刘勇
李航
仇丽娟
封欣然
谭立明
ZHANG Xiaoyan;LI Qingxiang;LIU Yong;LI Hang;QIU Lijuan;FENG Xinran;TAN Liming(Department of Clinical Laboratory Science,the Third Hospital of Nanchang,Nanchang 330009,Jiangxi Province,China;Department of Clinical Laboratory Science,the Second Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2021年第9期783-788,共6页
China Oncology
基金
江西省科技厅科技计划项目(20171BAB205067)
江西省中医药科研课题(2019A378)。